Prevalence and risk factors of metabolic dysfunction‐associated steatotic liver disease in south Central Uganda: A cross‐sectional survey
Alimentary Pharmacology & Therapeutics · 2024
DOI: 10.1111/apt.17931 ↗At a glance
Journal article in Alimentary Pharmacology & Therapeutics, 2024. Written by Rocio Enriquez and 12 co-authors. Institution: Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden. Major MEDLINE topics: HIV Infections, Metabolic Diseases, Fatty Liver, Cardiovascular Diseases. Cited 4 times so far (Crossref); 42 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: CDC HHS, NIMH NIH HHS, NICHD NIH HHS.
Abstract (original language)
Background
Despite numerous risk factors and serious consequences, little is known about metabolic dysfunction‐associated steatotic liver disease (MASLD) at population level in Africa.
Aim
The aim of the study was to estimate the prevalence and risk factors of MASLD in people living with and without HIV in Uganda.
Methods
We collected data from 37 communities in South Central Uganda between May 2016 and May 2018. We estimated MASLD prevalence using the fatty liver index and advanced liver fibrosis using the dynamic aspartate‐to‐alanine aminotransferase ratio. We collected additional data on sociodemographics, HIV and cardiovascular disease (CVD) risk factors. We used multivariable logistic regression to determine the association between HIV, CVD risk factors and MASLD.
Results
We included 759 people with HIV and 704 HIV‐negative participants aged 35–49. MASLD prevalence was 14% in women and 8% in men; advanced liver fibrosis prevalence was estimated to be
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.
- Rakai Health Sciences Program, Kalisizo, Uganda.
- Jönköping International Business School, Jönköping University, Jönköping, Sweden.
- Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
- Division of Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
ORCID profiles: Hannes Hagström, Helena Nordenstedt
Funding
- CDC HHS
- NIMH NIH HHS
- NICHD NIH HHS
- NIAID NIH HHS
- National Center for Child Health and Development
- National Institute of Allergy and Infectious Diseases
- Vetenskapsrådet
- Centers for Disease Control and Prevention
Cite
APA
Enriquez, R., Homsi, M., Ssekubugu, R., Nabukalu, D., Zeebari, Z., Marrone, G., Gigante, B., Chang, L. W., Reynolds, S. J., Nalugoda, F., Ekström, A. M., Hagström, H., & Nordenstedt, H. (2024). Prevalence and risk factors of metabolic dysfunction‐associated steatotic liver disease in south Central Uganda: A cross‐sectional survey. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17931
Vancouver
Enriquez R, Homsi M, Ssekubugu R, Nabukalu D, Zeebari Z, Marrone G, et al. Prevalence and risk factors of metabolic dysfunction‐associated steatotic liver disease in south Central Uganda: A cross‐sectional survey. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.17931
BibTeX
@article{Enriquez2024,
author = {Enriquez, Rocio and Homsi, Mahmoud and Ssekubugu, Robert and Nabukalu, Dorean and Zeebari, Zangin and Marrone, Gaetano and Gigante, Bruna and Chang, Larry W and Reynolds, Steven J and Nalugoda, Fred and Ekström, Anna Mia and Hagström, Hannes and Nordenstedt, Helena},
title = {Prevalence and risk factors of metabolic dysfunction‐associated steatotic liver disease in south Central Uganda: A cross‐sectional survey},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
doi = {10.1111/apt.17931}
}
EUVIMED